Vifor Pharma

Vifor Pharma
Industry Pharmaceutics
Founded 2008
Headquarters St. Gallen, Switzerland
Key people
 Etienne Jornod (Chairman)
Revenue 1'342 million CHF (2017)
Number of employees
 2,650 (50% in Switzerland) (2017)
Website www.viforpharma.com

Vifor Pharma – formerly the Galenica Group[1] – is a Swiss global specialty pharmaceutical company.[2]

History

The company was founded in 2008. Vifor Pharma was a result of the acquisition of the former Aspreva Pharmaceuticals.[3] Under this umbrella, the former pharmaceutical companies of Galenica – Vifor (International), Vifor and Potters – were merged into a fully integrated pharmaceutical company. In September 2009, Galenica acquired OM Pharma, a pharmaceutical company active in the field of immunology.[4] The US company Relypsa was taken over by Galenica in September 2016[5] and integrated into Vifor Pharma.[6]

References

  1. ↑ "Galenica Santé gut gestartet". Neue Zürcher Zeitung. 7 April 2017. Retrieved 5 October 2017.
  2. ↑ "Wer wir sind". Vifor Pharma. Retrieved 5 October 2017.
  3. ↑ "Galenica says to offer $915 million for Aspreva". Reuters. 18 October 2007. Retrieved 5 October 2017.
  4. ↑ "Galenica acquiert la société biotech OM Pharma". Le Temps. 8 September 2009. Retrieved 5 October 2017.
  5. ↑ Sylwia Lasek, Ben Hirschler (21 July 2016). "Galenica to buy biotech firm Relypsa for $1.5 billion, ahead of split". Reuters. Retrieved 5 October 2017.
  6. ↑ "Geschichte". Vifor Pharma. Retrieved 5 October 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.